Drugs / recombinant interferon gamma
recombinant interferon gamma
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01957709 | Sep 2013 → Jun 2018 | myxoid liposarcoma, round cell liposarcoma, synovial sarcoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00002761 | Feb 1996 → Feb 2007 | leukemia | Columbia University | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00059878 | Aug 2003 → Jan 2005 | cancer of unknown primary site, infectious disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00616720 | Aug 2001 → Nov 2007 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00002505 | Aug 1992 → Aug 2002 | — | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00070187 | Nov 2003 → Jun 2005 | lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00003414 | Oct 1997 → May 2004 | graft versus host disease, lymphoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 3 | NCT00008203 | May 1996 → Dec 2005 | female breast carcinoma | Herbert Irving Comprehensive Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT00002796 Background | May 1997 → Dec 2004 | colon mucinous adenocarcinoma, colon signet ring cell adenocarcinoma, rectal signet ring cell adenocarcinoma, rectum mucinous adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00002475 Background | Apr 1991 → Dec 2007 | breast cancer, colorectal cancer, kidney cancer, lung cancer +2 | St. Vincent Medical Center - Los Angeles | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant interferon gamma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003414 ↗ |
| Known as | IFN-gamma | “combined cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28 and interferon gamma (IFN-gamma) 0.025 mg/m(2) SQ every 2 days from day +7 to +28” PMID 17563739 ↗ Jun 2007 |
| Known as | IFN-γ | “We previously demonstrated that both MHC expression and T-cell infiltration can be increased using systemic interferon gamma (IFN-γ), which could improve the efficacy of ACT for SS.” PMID 32269142 ↗ Apr 2020 |
| Known as | interferon gamma | “combined cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28 and interferon gamma (IFN-gamma) 0.025 mg/m(2) SQ every 2 days from day +7 to +28” PMID 17563739 ↗ Jun 2007 |
| Modality | Protein / enzyme biologic | “recombinant interferon gamma” NCT00002475 ↗ |
| Route | Subcutaneous | “100 MIU IFNgamma subcutaneously” PMID 12843799 ↗ Jul 2003 |